As independent confirmation of these data, experiments utilizing the SMYD2 inhibitor, LLY‐507, demonstrated that targeting SMYD2 was effective in inhibiting the proliferation of U373 glioma cells (Figure 6F). Here, SMYD2 is linked to glioma.